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Abstract  The  authors  report  the  case  of  a  young  woman  presenting  with  asymptomatic  hyper-
transaminasemia  whose  etiologic  investigation  led  to  the  diagnosis  of  celiac  disease.  The
concomitant  existence  of  antinuclear  and  anti-smooth  muscle  antibodies  and  of  elevated  serum
immunoglobulin  G  concentrations  raised  the  hypothesis  of  autoimmune  hepatitis,  reason  for
performing  a  liver  biopsy.  The  ﬁnal  diagnosis  was  celiac  hepatitis,  resolved  with  dietary  treat-
ment alone.  Celiac  disease  is  a  systemic  disorder  primarily  affecting  the  small  bowel.  A  variety
of liver  manifestations  have  been  described  and  there  is  an  established  association  with  autoim-
mune hepatic  disorders.  Isolated  elevation  of  aminotransferases  is  the  most  common  hepatic
presentation,  usually  reversible  with  gluten  avoidance.  Although  rarely  necessary,  liver  biopsy
may be  crucial  in  selected  cases.
© 2012  Sociedade  Portuguesa  de  Gastrenterologia  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Elevac¸ão das  aminotransferases  na  doenc¸a celíaca:  hepatite  celíaca  ou  autoimune?
Resumo  Os  autores  relatam  o  caso  de  uma  jovem,  assintomática,  com  elevac¸ão  das
aminotransferases,  cuja  investigac¸ão  etiológica  conduziu  ao  diagnóstico  de  doenc¸a  celíaca.
A existência  concomitante  de  anticorpos  antinucleares  e  antimúsculo  liso  e  de  elevac¸ão  dos
níveis de  imunoglobulina  G  deu  origem  à  hipótese  diagnóstica  de  hepatite  autoimune,  tendo-
se realizado  uma  biópsia  hepática.  O  diagnóstico  ﬁnal  foi  de  hepatite  celíaca,  com  resoluc¸ão
completa  em  resposta  à  terapêutica  nutricional.  A  doenc¸a  celíaca  é  uma  patologia  sistémica
com envolvimento  primário  do  intestino  delgado.  Estão  descritas  várias  manifestac¸ões  hepáti-
cas, existindo  uma  associac¸ão  com  as  doenc¸as  hepáticas  autoimunes.  A  elevac¸ão  isolada  das
aminotransferases  é  a  forma  de  apresentac¸ão  mais  comum,  sendo  geralmente  reversível  com
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a  eliminac¸ão  do  glúten  da  dieta.  Apesar  de  raramente  necessária,  a  biópsia  hepática  pode  ser
determinante  em  casos  selecionados.
© 2012  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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oIntroduction
Celiac  disease  (CD)  is  an  autoimmune  disorder  induced  by
dietary  gluten.  It  is  characterized  by  a  chronic  inﬂamma-
tory  state  of  the  small  intestinal  mucosa,  resulting  in  villous
atrophy  that  resolves  with  a  gluten  free  diet.  There  is  a  wide
spectrum  of  presentations,  varying  from  a  clinically  silent
form  to  the  classical  malabsorption  syndrome.1 Although
primarily  affecting  the  small  bowel,  CD  is  a  multisystem  ill-
ness.  The  potential  target  organs  include  the  liver,  pancreas,
heart,  kidney,  thyroid  gland,  bone,  skin  and  nervous  system,
giving  rise  to  a  variety  of  extraintestinal  manifestations.1,2
A  number  of  hepatobiliary  disorders  have  been  docu-
mented  in  patients  with  CD.  The  most  common  pattern
of  liver  damage  is  a  gluten  sensitive  form  of  hepatitis
(celiac  hepatitis).  The  usual  manifestation  consists  of  an  iso-
lated  elevation  of  aminotransferases.  In  this  context,  liver
biopsy  is  usually  of  limited  value,  since  the  histological  ﬁnd-
ings  are  nonspeciﬁc  and  there  is  a  complete  response  to
dietary  treatment.2 More  rarely,  CD  is  associated  with  a
group  of  liver  disorders  sharing  common  genetic  factors  and
immunopathogenesis,  such  as  autoimmune  hepatitis  (AIH),
primary  biliary  cirrhosis  (PBC)  and  primary  sclerosing  cholan-
gitis  (PSC).  If  this  is  the  case,  gluten  withdrawal  is  usually
insufﬁcient  to  normalize  liver  tests  and  to  prevent  progres-
sive  liver  damage  and  a  speciﬁc  management  is  required.3,4
Case report
A  21-year-old  woman  was  referred  to  evaluation  because
of  an  unclear  elevation  of  liver  enzymes.  The  patient  was
asymptomatic  and  routine  laboratory  tests  made  six  months
earlier  incidentally  detected  a  1.5  to  2-fold  elevation  of
both  aspartate  aminotransferase  (AST)  and  alanine  amino-
transferase  (ALT).  She  denied  any  history  of  alcohol  or  illicit
drugs  use  and  she  was  not  taking  any  medications,  includ-
ing  nonprescription  ones.  There  was  no  evidence  of  risk
factors  for  viral  hepatitis.  Her  past  medical  history  was
unremarkable  and  no  family  history  of  liver  or  gastrointesti-
nal  disorders  could  be  identiﬁed.  The  physical  examination
was  normal,  with  a  body  mass  index  (BMI)  of  19  kg/m2
and  no  signs  of  liver  disease.  The  initial  laboratory  study
evidenced  AST  40  U/L  (upper  limit  of  reference,  31  U/L)
and  ALT  64  U/L  (upper  limit  of  reference,  34  U/L),  with
normal  alkaline  fosfatase,  -glutamyl  transferase,  bilirubin
and  normal  hemogram.  Abdominal  ultrasound  examination
was  normal.  A  complete  screen  for  the  possible  etiology
of  abnormal  liver  tests  was  performed.  Serologic  markers
for  viral  hepatitis  were  negative.  Transferrin  saturation,
ferritin,  ceruloplasmin,  1-antitrypsin  and  thyroid  func-
tion  tests  were  normal.  The  serum  protein  electrophoresis
and  immunoglobulin  study  disclosed  an  elevation  of  serum
o
w
hmmunoglobulin  (Ig)  G  concentrations  (19.7  g/L;  normal
--16  g/L)  and  low  serum  IgA  (0.24  g/L;  normal  0.7--4  g/L).
he  autoantibody  proﬁle  was  characterized  by  positive
ntinuclear  (+++),  anti-double-strand  DNA  (6.1  U/mL;  nor-
al  < 4.2  U/mL)  and  anti-smooth  muscle  antibodies  (++++,
ctin  pattern),  plus  a  positivity  to  IgG  anti-transglutaminase
528  U/mL;  positive,  >10  U/mL)  and  anti-gliadin  antibodies
600  U/mL;  positive  >  10  U/mL);  anti-endomysial  antibodies
ere  negative.  The  patient  underwent  an  upper  gastroin-
estinal  endoscopy,  which  showed  a  slight  loss  of  folds  in
he  second  portion  of  the  duodenum.  Multiple  biopsies  were
btained  in  this  location,  revealing  a  complete  villous  atro-
hy,  crypt  lengthening  and  markedly  increased  number  of
ntraepithelial  lymphocytes  (Fig.  1),  histopathological  ﬁnd-
ngs  typical  of  celiac  disease  (with  a  destructive  pattern,
c  type  according  to  the  Marsh--Oberhuber  classiﬁcation).
ince  the  differential  diagnosis  of  AIH  versus  celiac  hepati-
is  was  unclear,  it  was  decided  to  perform  a  liver  biopsy.
he  biopsy  revealed  minimal  macrovesicular  steatosis  and
epatocellular  reactive  changes,  with  no  evidence  of  inter-
ace  hepatitis  (Fig.  2),  all  nonspeciﬁc  ﬁndings,  not  consistent
ith  AIH.  At  this  point,  the  simpliﬁed  AIH  score  was  6,  indi-
ating  a  probable  diagnosis  of  AIH.  According  to  the  overall
linicopathological  data,  the  liver  abnormalities  were  pri-
arily  attributed  to  celiac  disease.  The  patient  received
ietary  counseling  and  started  on  a  gluten-free  diet  alone.
fter  6  months  the  laboratory  reassessment  evidenced  a
omplete  normalization  of  aminotransferases  (AST  25  U/L,
LT  22  U/L)  and  decreasing  IgG  anti-transglutaminase  levels
342  U/mL);  antinuclear  and  anti-smooth  muscle  antibodies
emained  positive.  Her  BMI  was  21  kg/m2.
iscussion
epatic  abnormalities  are  common  extraintestinal  man-
festations  of  CD.  They  may  arise  in  patients  with  the
lassical  malabsorption  syndrome  or  may  be  the  sole  presen-
ation  in  some  cases.2 Approximately  27%  of  adult  patients
ith  untreated  classic  CD  have  elevated  transaminases.
onversely,  CD  is  the  potential  cause  for  cryptogenic  hyper-
ransaminasemia  in  3--4%  of  cases.5
CD  not  only  may  itself  injure  the  liver  but  it  may  also
oexist  with  other  chronic  liver  diseases  and  modify  their
linical  impact.2 Two  main  forms  of  liver  damage  are  recog-
ized:  the  nonspeciﬁc  celiac  hepatitis  and  the  autoimmune
ediated.  It  is  not  clearly  deﬁned  if  these  two  forms  are  dis-
inct  entities  or  only  different  ends  of  a  continuous  spectrum
f  liver  injury.6,7 Fatty  liver  disease,  viral  hepatitis  and  iron
verload  liver  disease  have  also  been  described  in  patients
ith  CD.3,6
A  nonspeciﬁc  form  of  liver  disease,  the  so-called  celiac
epatitis,  is  the  most  common  form  of  hepatic  involvement
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Figure  1  Duodenal  biopsy.  (A)  Severe  mucosal  lesion  with  severe  villous  blunting,  hypertrophic  crypts  and  increased  chronic
inﬂammation  of  the  lamina  propria  (hematoxylin  and  eosin,  100×).  (B)  CD3  highlights  an  increased  number  of  intraepithelial
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l-lymphocytes  in  the  atrophic  villus  (200×).
n  CD.  The  pathogenesis  remains  poorly  understood.  Malnu-
rition,  with  its  metabolic  effects,  is  one  of  the  proposed
ypothesis,  although  nowadays  this  is  an  uncommon  fea-
ure  of  CD  patients.5 An  alternative  possible  mechanism
s  the  direct  effect  of  antigens  absorbed  from  the  gut,
s  a  result  of  an  increased  permeability  of  the  inﬂamed
ntestinal  mucosa.8,9 Against  this  hypothesis  is  the  absence
f  correlation  between  intestinal  histological  changes  and
he  severity  of  hepatic  dysfunction.10 On  the  other  hand,
he  normalization  of  aminotransferases  with  the  removal  of
luten  from  the  diet  suggests  a  causal  relationship  between
luten  intake/intestinal  damage  and  liver  injury.2 Recently,
t  has  been  hypothesized  that  anti-endomysial  antibodies
ay  also  play  a  direct  role.9 Most  patients  with  this  form
f  hepatitis  have  no  symptoms  or  signs  of  liver  disease.9--11
ild  to  moderate  serum  levels  of  AST  and/or  ALT  (with  an
ST/ALT  ratio  less  than  one)  are  the  most  common  and
ften  only  laboratory  manifestations,  whereas  the  bilirubin,
lkaline  fosfatase  and  -glutamyl  transferase  are  normal.2,11
sually,  autoantibodies  other  than  the  CD  ones  are  not
resent.6 Liver  biopsy  is  of  limited  value  in  this  context
ue  to  the  nonspeciﬁc  nature  of  the  histological  ﬁndings  and
he  high  rate  of  response  after  gluten  exclusion.2 The  his-
ological  analysis  most  commonly  shows  no  abnormalities  or
on-speciﬁc  hepatitis,  but  occasionally  ﬁbrosis  and  cirrhosis
an  occur.11,12 Studies  have  reported  non-speciﬁc  ﬁndings
ike  focal  ductular  proliferation,  bile  duct  obstruction,
uppfer  cell  hyperplasia,  minimal  macrovesicular  steato-
is  and  minor  inﬂammatory  inﬁltration.6,13 Nevertheless,
iver  biopsy  may  be  useful  in  the  case  of  coexisting  speciﬁc
epatic  disorder  or  when  there  is  a  lack  of  response  to  diet.2
he  decision  to  perform  it  must  therefore  be  individualized.
 gluten-free  diet  leads  to  aminotransferases  normalization
n  75--95%  of  cases  within  a  year.10,11,14 In  those  patients
ith  persistent  elevations  despite  good  compliance  to  gluten
xclusion,  an  alternative  etiology  should  be  investigated.
arely,  CD-associated  liver  disease  can  manifest  as  chronic
epatitis,  cirrhosis  and  acute  liver  failure.2,12,14 Screening
or  CD  must  be  considered  in  all  patients  presenting  with
bnormal  liver  tests  and  cryptogenic  cirrhosis.5,11,12
e
o
iigure  2  Liver  biopsy.  Nonspeciﬁc  changes  with  clusters  of
allooned  hepatocytes  (hematoxylin  and  eosin,  100×).
There  is  a  well  established  relation  between  CD  and
utoimmune  mediated  chronic  liver  diseases,  probably  shar-
ng  immunological  mechanisms  and  susceptibility.  AIH,  PBC
nd  PSC,  with  its  typical  histological  features,  have  all  been
eported.1,3,4,12,13,15 Two  studies  found  that  AIH  patients  have
 higher  prevalence  of  CD,  from  4%  to  6.4%.15,16 Few  of
hese  patients  have  the  classical  intestinal  manifestations,
nstead  they  tend  to  have  nonspeciﬁc  symptoms  such  as
atigue  and  malaise.4,8,10 The  clinical  impact  of  gluten  with-
rawal  on  the  outcome  of  the  liver  disorder  remains  unclear,
ut  it  is  hypothesized  that  it  may  play  a  role  in  preventing
he  evolution  to  end-stage  liver  disease.2,12 Nevertheless
ietary  treatment  is  necessary  to  improve  symptoms  of  CD
if  present)  and  to  avoid  severe  chronic  complications.1 Test-
ng  for  AIH  is  recommended  in  CD  patients  with  abnormal
iver  tests.  Conversely,  screening  for  CD  should  be  consid-
red  for  patients  with  AIH,  irrespectively  of  the  existence
f  gastrointestinal  complaints.1,2
The  prevalence  of  PBC  is  increased  from  3  to  20-fold
n  patients  with  CD,  as  demonstrated  by  two  large  cohort
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studies.17,18 On  the  other  hand,  CD  is  more  prevalent  in
PBC  patients,  from  3%  to  7%.4 It  should  be  noted  that
anti-mitochondrial  antibody-negative  PBC  and  false-positive
anti-transglutaminase  antibodies  have  been  reported  in  this
context.19,20 As  in  the  case  of  AIH,  the  impact  of  gluten
avoidance  is  not  well  established,  but  it  is  determinant  to
improve  symptomatic  CD  and  to  prevent  complications.2,20
A  relation  between  CD  and  PSC  has  been  suggested  in  sev-
eral  case  reports  and  in  a  population-based  study.  However
the  strength  of  this  association  is  not  clearly  determined
and  the  beneﬁt  of  gluten  exclusion  from  the  diet  was  not
yet  demonstrated.2,13
Nonalcoholic  fatty  liver  disease  (NAFLD)  and  steato-
hepatitis  (NASH)  are  common  disorders  in  the  general
population  and  in  celiac  patients.  Studies  found  a  preva-
lence  of  CD  in  about  3%  of  individuals  with  NAFL  and  NASH.21
Obesity,  a  major  risk  factor  for  nonalcoholic  liver  disease,
is  common  in  patients  with  CD  not  only  after  but  also
before  gluten  withdrawal,  which  could  explain  the  associ-
ation  between  these  disorders.22 Additional  etiopathogenic
mechanisms  may  be  the  increased  intestinal  permeability,
resulting  in  bacterial  translocation  and  production  of  proin-
ﬂammatory  factors,  and  malabsorption  leading  to  chronic
deﬁciency  of  lipotropic  molecules.23,24 The  correlations
among  CD,  obesity  and  liver  disease  must  be  taken  into
account  when  establishing  the  diagnosis  and  treating  celiac
patients  presenting  with  elevated  liver  enzymes.
Acute  liver  failure  and  advanced  liver  disease  deserve
a  special  consideration.  There  are  several  cases  reported
in  literature  and  CD  was  found  to  be  up  to  10  times  more
frequent  among  patients  with  chronic  liver  disease  than
in  the  general  population.25 The  study  by  Kaukinen  and
colleagues12 found  a  high  prevalence  of  CD  (4.3%)  in  patients
who  underwent  liver  transplantation.  Autoimmune  disor-
ders,  such  as  PBC,  PSC  and  AIH  were  the  main  etiologies
of  end-stage  liver  disease  leading  to  transplantation.  This
study  also  describes  4  cases  of  patients  with  advanced  liver
disease  who  were  found  to  have  CD,  all  of  them  improv-
ing  signiﬁcantly  their  liver  function  with  gluten  withdrawal.
Some  of  the  patients  in  both  groups  had  no  apparent  symp-
toms  or  signs  suggesting  CD.  The  authors  emphasize  that  the
early  detection  and  treatment  of  CD  may  prevent  the  pro-
gression  to  end-stage  liver  failure.  Therefore,  CD  must  be
screened  in  patients  with  autoimmune  liver  disease  or  hep-
atitis/cirrhosis  of  unknown  etiology  and  in  those  undergoing
liver  transplantation.  Moreover,  an  essential  component  of
the  clinical  surveillance  after  transplantation  in  CD  patients
is  the  assessment  of  compliance  with  a  gluten-free  diet.
The  present  case  illustrates  the  association  between
CD  and  liver  disease.  Our  patient  was  a  young  woman
presenting  with  asymptomatic  hypertransaminasemia.  The
initial  CD  screening  was  based  on  autoantibodies,  followed
by  duodenal  biopsy.  One  peculiarity  of  this  patient  was  the
coexistence  of  a  selective  IgA  deﬁciency,  requiring  that  the
screening  for  CD  was  carried  out  using  IgG  autoantibodies.
This  immune  defect  is  one  of  the  conditions  known  to  be
associated  with  CD.1 We  emphasize  the  importance  of  a  con-
ﬁrmatory  duodenal  biopsy,  since  false  positive  serological
tests  for  CD  can  occur  in  patients  with  chronic  liver  dis-
ease  and  IgG  are  less  speciﬁc.1,7 Another  relevant  feature
of  our  case  was  the  autoantibody  proﬁle  suggestive  of  AIH,epatitis?  165
iving  rise  to  this  etiological  hypothesis.  We  have  chosen
o  perform  a  liver  biopsy,  which  proved  to  be  determinant
or  the  ﬁnal  diagnosis  in  this  speciﬁc  case.  Another  possible
ption  would  be  to  recommend  gluten  withdrawal,  control
iver  enzymes  after  6--12  months  and  continue  the  investi-
ation  only  if  elevated  levels  persisted.  As  expected  in  this
atient,  liver  tests  completely  normalized  within  6  months
f  a  gluten-free  diet.
This  case  emphasizes  the  need  to  screen  CD  in  patients
ith  cryptogenic  hypertransaminasemia,  irrespective  of  the
xistence  of  gastrointestinal  symptoms.  It  also  exempliﬁes
 particular  situation  in  which  a liver  biopsy  is  useful  to
stablish  the  diagnosis  of  celiac  hepatitis.
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